NCT06424340View on ClinicalTrials.gov

MB-dNPM1-TCR.1 in Relapsed/refractory AML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Leukemia, Myeloid, Acute
Interventions
BIOLOGICAL

MB-dNPM1-TCR.1

T Cell Receptor (TCR) T cell therapy

Trial Locations (1)

2333

RECRUITING

Leiden University Medical Center, Leiden

Sponsors
All Listed Sponsors
lead

Miltenyi Biomedicine GmbH

INDUSTRY